2.Research Advances of Pan-negative Type of Non-small Cell Lung Cancer.
Li SUN ; Zhicheng XIONG ; Chengbo HAN
Chinese Journal of Lung Cancer 2018;21(2):129-138
In recent years, series of driver genes, such as EGFR, KRAS/NRAS, BRAF, PIK3CA, ALK and ROS1 and so on, have been found in non-small cell lung cancer (NSCLC) one after another with the development of molecular detecting technology. Targeted drugs bring benefits for these NSCLC patients with driver gene variations. However, some NSCLC did not have any known driver gene variations; we called it pan-negative lung cancer. In this paper, we summarize the concept, clinical pathological characteristics, the epidemiological characteristics, treatment and prognosis of pan-negative NSCLC.
Carcinoma, Non-Small-Cell Lung
;
diagnosis
;
drug therapy
;
genetics
;
pathology
;
Humans
;
Lung Neoplasms
;
diagnosis
;
drug therapy
;
genetics
;
pathology
;
Mutation
;
Prognosis
3.Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma with COX7A2L-ALK Fusion: A Case Report and Literature Review.
Jiao YUAN ; Ruili PAN ; Wei ZHONG ; Mengzhao WANG
Chinese Journal of Lung Cancer 2023;26(4):319-324
Lung cancer is the most common in incidence and mortality worldwide. With the development of next generation sequencing (NGS) detection technology, more and more patients with rare anaplastic lymphoma kinase (ALK) fusion mutations were detected. A case of advanced lung adenocarcinoma with rare COX7A2L-ALK (C2:A20) fusion detected by NGS was reported in Peking Union Medical College Hospital, and all cases with rare ALK fusion mutations were searched from medical datebase from January 1, 2014 to March 31, 2021, to investigate the treatment of rare ALK fusion mutations with ALK inhibitors. The best response of the patient was assessed as partial response (PR) with Ceritinib treatment. By literature review, 22 cases of rare ALK fusion were reported in 19 articles. Combined with this case, 23 cases were analyzed. The objective response rate (ORR) was 82.6% (19/23) and disease control rate (DCR) was 95.7% (22/23) for rare ALK fusions patients treated with ALK inhibitors. Lung adenocarcinoma patients with rare ALK fusion could benefit from ALK inhibitors.
.
Humans
;
Anaplastic Lymphoma Kinase/genetics*
;
Lung Neoplasms/diagnosis*
;
Crizotinib
;
Adenocarcinoma of Lung/genetics*
;
Protein Kinase Inhibitors/pharmacology*
;
Oncogene Proteins, Fusion/genetics*
4.Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer.
Chinese Journal of Lung Cancer 2018;21(9):686-691
Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutations and ALK rearrangements are mutually exclusive, but isolated cases or small sample research with concomitant EGFR and ALK alterations have been constantly reported. The co-occurrence of EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular, the frequency of EGFR/ALK co-alterations was about 1%, however, little has been known about clinicopathologic feature and treatment. This review summarized published case report, EGFR and ALK alterations are common in female, Asian origin, never smoker, IV stage, and denocarcinomas. First-line treatment can choose EGFR or ALK tyrosine kinase inhibitors (TKIs). However, studies about the origin and resistance mechanism in EGFR/ALK co-alterations are little, require more experimental and clinical research.
.
Anaplastic Lymphoma Kinase
;
Carcinoma, Non-Small-Cell Lung
;
diagnosis
;
enzymology
;
genetics
;
ErbB Receptors
;
genetics
;
Humans
;
Lung Neoplasms
;
diagnosis
;
enzymology
;
genetics
;
Mutation
;
Prognosis
;
Receptor Protein-Tyrosine Kinases
;
genetics
5.Bioinformatics Analysis of DNA Methylation in the Promoters of LincRNA in Lung Adenocarcinoma.
Wen ZHANG ; Shaojun LI ; Nannan GUO ; Yingnan ZHAO
Chinese Journal of Lung Cancer 2018;21(6):470-475
BACKGROUND:
Previous studies have found the lincRNAs play important roles in the occurrence and development of lung adenocarcinoma, but their regulated mechanims are still unclear. The aim of this study is to evaluate the relationship between DNA methylation and lincRNA expression, and the effect of prognosis in lung adenocarcinoma.
METHODS:
The whole genome Illumina Methylation 450 DNA methylatiuon data and RNAseq for lung adenocarcinoma were download from TCGA. DNA methylation around lincRNA and their relationship to gene expression were analyzed. Their contribution to lung adenocarcinoma were further analyzed by comparing DNA methylation and lincRNA expression in tumor and adjacent tissues.
RESULTS:
The methylation level in promoter region was lower than other positions in lincRNA, and was negatively correlated with gene expression. There were 427 lincRNA genes showed differential DNA methylation in their promoter regions in tumor and adjacent tissues. Among these, 15 lincRNA genes showed differential gene expression and negatively correlated with DNA methylation, including FENDRR (a tumor progression and metastasis gene) whose high methylation in its promoter showed poor survival in lung adenocarcinoma.
CONCLUSIONS
The expression of lincRNA can be regulated by DNA methylation in their promoter regions, and the level of DNA methylation is related to patient prognosis in lung adenocarcinoma.
Adenocarcinoma
;
diagnosis
;
genetics
;
Adenocarcinoma of Lung
;
Computational Biology
;
DNA Methylation
;
Humans
;
Lung Neoplasms
;
diagnosis
;
genetics
;
Prognosis
;
Promoter Regions, Genetic
;
genetics
;
RNA, Long Noncoding
;
genetics
;
Survival Analysis
6.Combination of phage display and SEREX for screening early lung cancer associated antigens.
Na YUAN ; Guo-hong XIN ; Xiao-xiao ZUO ; Shang-ke HUANG ; Ying WANG ; Lei HOU ; Tian-jie QIN ; Xin-han ZHAO
Journal of Zhejiang University. Medical sciences 2014;43(4):388-396
OBJECTIVETo screen out effective lung cancer associated antigens for early diagnosis in order to improve the level of early diagnosis.
METHODSA T7 phage display cDNA library of human early lung cancer was developed. And then differential phage clones were picked out to be sequenced and bioinformatically analyzed. With the 8 screened differential phage clones a lung cancer associated antigen microarray was established to evaluate the single or combined roles of all the selected antigens in the diagnosis of lung cancer by the reaction of the antigens plus serum from normal subjects and patients with lung cancer, respectively.
RESULTSThe titer of the constructed cDNA library was 3.71×10 (6); pfu/ml and the number of phage was 1.11×10 (6); pfu, with a recombination rate of cDNA library over 90%. Nine differential phage clones were initially screened out, but the genes of two antigens (A42 and A83) were found the same. Bioinformatics analyses showed that the genes of the 8 antigens were known before and they were all proven to be related with tumor except A64. The positive reaction rates of the 8 antigens with serum from lung cancer patients were significantly higher than that with serum from normal subjects (Ps<0.05). When keeping specificity no less than 60%, the sensitivity of each antigen in predicting lung cancer alone was under 70% and the areas under curve (AUC) of the antigens were all under 0.8. However, when all the antigens were combined to detect lung cancer, the sensitivity and specificity was 90.8% and 94.1%, respectively, and AUC reached up to 0.969.
CONCLUSIONA T7 phage display cDNA library with a good quality of capacity, recombination rate and representativeness of human early lung cancer was successfully developed, and 8 lung cancer associated antigens were screened out. A combination of the 8 antigens can greatly improve their value to diagnose lung cancer with a higher sensitivity and specificity (both above 90%).
Antigens, Neoplasm ; genetics ; Early Detection of Cancer ; methods ; Gene Library ; Humans ; Lung Neoplasms ; diagnosis ; genetics ; Sensitivity and Specificity
7.MicroRNA and Lung Cancer: A Mini Review.
Lei TUO ; Xiaoshuai CHU ; Sha SHA ; Xun ZHANG
Chinese Journal of Lung Cancer 2018;21(9):727-730
MicroRNAs (miRNAs) a class of non-coding RNAs about 22 nt in size that are found in a wide range of organisms from plants, viruses to humans. MicroRNA has a wide range of biological functions. It can recruit related RNA enzymes and lead to mRNA degradation after binding to mRNA specificity, thus blocking the expression of protein encoding genes and then affecting their biological functions. In recent years, microRNA has been found to be closely related to the biological behaviors, such as the occurrence, development, invasion and metastasis of multiple human malignant carcinomas, and play a regulatory role in the above biological phenotypes. Lung cancer is the highest incidence of malignancy. The exact molecular mechanism of its occurrence and development has not been fully elucidated. Previous studies have shown that microRNA plays an important role in lung tumor suppressor gene inactivation, oncogene activation and epigenetics. At the same time, there are also reports that there is a significant difference in the expression of microRNA in patients with lung cancer and benign lung diseases. This differential expression provides a basis for the feasibility of microRNA as a diagnostic and pre biological marker for lung cancer.
.
Humans
;
Lung Neoplasms
;
diagnosis
;
genetics
;
pathology
;
MicroRNAs
;
genetics
;
Neoplasm Invasiveness
;
Neoplasm Metastasis
8.Progress in pulmonary enteric adenocarcinoma.
Ying ZUO ; Hua BAI ; Jian Ming YING ; Jie WANG
Chinese Journal of Oncology 2022;44(4):321-325
Pulmonary enteric adenocarcinoma (PEAC), as a rare histologic subtype of primary lung adenocarcinoma, is defined as an adenocarcinoma in which the enteric component exceeds 50%. It is named after its shared morphological and immunohistochemical features with colorectal cancer. While with such similarity, the differential diagnosis of PEAC and lung metastatic colorectal cancer is a great challenge in the clinic. PEAC may originate from the intestinal metaplasia of respiratory basal cells stimulated by risk factors such as smoking. Current studies have found that KRAS is a relatively high-frequency mutation gene, and other driver gene mutations are rare. In terms of immunohistochemistry, in pulmonary enteric adenocarcinoma, the positive rate was 88.2% (149/169) for CK7, 78.1% (132/169) for CDX2, 48.2% (82/170) for CK20 and 38.8% (66/170) for TTF1. As for clinical features, the average age of onset for pulmonary enteric adenocarcinoma was 62 years, male patients accounted for 56.5% (35/62), smokers accounted for 78.8% (41/52), and 41.4% (24/58) of the primary lesion was located in the upper lobe of the right lung. In terms of treatment, conventional non-small cell lung cancer (NSCLC) regimens rather than colorectal cancer regimens are now recommended. There is still an urgent need for more basic and clinical research, in-depth exploration of its molecular feature and pathogenesis from the level of omics and other aspects, to help diagnosis and differential diagnosis, and find the optimal chemotherapy regimen, possibly effective targeted therapy and even immunotherapy.
Adenocarcinoma/pathology*
;
Adenocarcinoma of Lung/pathology*
;
Biomarkers, Tumor
;
Carcinoma, Non-Small-Cell Lung/diagnosis*
;
Colonic Neoplasms/pathology*
;
Diagnosis, Differential
;
Humans
;
Lung Neoplasms/genetics*
;
Male
;
Middle Aged